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C lobetasol propionate, probably the most potenttopical corticosteroid yet developed,' has re-
cently been approved for use in the United States.
Confirming vasoconstrictor assay predictions of clinical
effectiveness,^ clobetasol has been shown in double-
blind, multicenter trials '̂* to be statistically significantly
superior in 0.05% cream formulation to 0.05% fluo-
cinonide cream and in 0.05% ointment formulation to
0.05% betamethasone dipropionate in an optimized
vehicle in the treatment of psoriasis. Clobetasol pro-
pionate cream 0.05% has also been compared with
the potent topical corticosteroid cream haleinonide
0.1% in a recent two-center study. The results of
the 2-week randomized double-blind, left-right paired
trial (the most accurate comparative measure of
topical corticosteroid efficacy in psoriasis) are pre-
sented below.
Materials and Methods
Clobetasol and haleinonide creams were applied twice
daily for 2 weeks, in quantities not exceeding 50 g per week,
by 73 patients with moderate-to-severe psoriasis. (Identical
blind-labeled tubes of cream were randomly marked for use
on patients' right or left sides.) Investigator preference and
patient preference were assessed on treatment days 3, 7,
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and 14. Treatment preferences were again assessed 2 weeks
after discontinuation of therapy, as was the incidence of re-
lapse by treatment side.
Results
By investigators' preference, a significant treatment
difference in favor of clobetasol became evident as
early as the third day and more than doubled by two
weeks (Fig. 1). After 2 weeks without therapy, the mar-
gin of difference widened further, to 8 1 % clobetasol-
treated sides preferred versus 3% halcinonide-treated
sides preferred. Patient preference showed a similar
pattern (Fig. 1}. Also, significantly fewer patients
showed relapse on the clobetasol side 2 weeks after
treatment was stopped (3% clobetasol versus 63%
haleinonide; p < 0.001, McNemar's test).
Both drugs were well tolerated: seven instances of
mild adverse cutaneous reactions were reported for
clobetasol and nine for haleinonide.
Discussion
The results of this comparative trial of clobetasol and
haleinonide creams demonstrate a superior pharma-
cologic efficiency of clobetasol in psoriasis as measured
by degree, rate, and duration of healing. Similar results
have been reported in comparisons of clobetasoi and
fluocinonide creams^ and clobetasol and betametha-
sone dipropionate ointments'* and support the predic-
tive value of the vasoconstrictor assay in determining
clinical efficacy.
Drug Names


























































FIG. 1. Percent of treatment sides rated superior at curding to investigators and patients (preferences compared by sign test).
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Leprosy Testing
Despite the existence of apparently effective chemotherapy since the 1940s, the prevalence
ot leprosy in parts of many developing countries remains as high as 10 per 1000 of the population;
furthermore, strains that are resistant to the low-cost drug dapsone seem to be increasing in
frequency. Much effort is therefore being directed towards understanding the immune response
to Mycobacterium leprae and towards development of potentially prophylactic and therapeutic
vaccines to combat the disease. Epidemiological evidence suggests that the spread of leprosy is
mainly person to person and, since modern chemotherapy rapidly reduces the number of viable
organisms spread by an individual, the major source of transmission is likely to be individuals
who do not yet have symptoms. This may be particularly true of patients with lepromatous disease,
in whom very large numbers of bacilli are present at the time of clinical diagnosis. One of the
principal goals of leprosy research is to develop tests that will allow identification and early treat-
ment of such individuals, with the aim of reducing transmission of the disease.—Sero/og/ca/ tests
for leprosy. Lancet 1986;l:533-535.

